NIH Public Access
Author Manuscript
Mol Cancer Res. Author manuscript; available in PMC 2009 September 1.

Published in final edited form as:
Mol Cancer Res. 2008 September ; 6(9): 1421–1430. doi:10.1158/1541-7786.MCR-07-2175.

Sox7 is an independent checkpoint for β-catenin function in prostate and colon epithelial cells

Lizheng Guo[1], **Diansheng Zhong**[1], **Stephen Lau**[2], **Xiuju Liu**[1], **Xue-Yuan Dong**[1], **Xiaodong Sun**[1], **Vincent W. Yang**[3], **Paula M. Vertino**[4], **Carlos Moreno**[5], **Vijay Varma**[2], **Dong Jin-Tang**[1], and **Zhou Wei**[1,5,6]

1*The Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia*

2*Department of Pathology, Atlanta VA Medical Center, Emory University School of Medicine, Atlanta, Georgia*

3*Department of Medicine, Emory University School of Medicine, Atlanta, Georgia*

4*Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia*

5*Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia*

6*Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia*

Abstract

The presence of somatic β-catenin mutations in some prostate cancers implies that aberrant WNT signaling is involved in the cancer's development. Although β-catenin stability is regulated by a multi-component destruction complex, mutational alterations of β-catenin or other components of the destruction complexes are rare in prostate tumors. Therefore, β-catenin may be regulated by another protein in the prostate. In fact, recent linkage and somatic deletion analyses in prostate cancers reveal a 1.4 Mb candidate tumor suppressor locus on 8p23.1, which includes the *Sox7* gene. Here we show that Sox7 protein expression was indeed down-regulated in 47% (15/32) of prostate adenocarcinomas. Also, *Sox7* mRNA was down-regulated in 60% of snap-frozen tumors. This down-regulation was found to be due to tumor-specific promoter hypermethylation, which was present in 48% (10/21) of primary prostate tumors and 44% (11/25) of prostate cancer cell lines/xenografts. We discovered that Sox7 protein physically interacts with β-catenin and suppresses β-catenin-mediated transcription by depleting active β-catenin. Furthermore, in HCT116 colorectal cancer cell lines with *Sox7* inactivation, ectopic *Sox7* expression suppressed cell proliferation and inhibited transcription that was activated by an endogenous mutant β-catenin. Even though nearly all colorectal cancers contain mutations in β-catenin or APC/Axin, epigenetic silencing of *Sox7* was still observed. These data suggest that *Sox7* is a tumor suppressor that functions as an independent checkpoint for β-catenin transcriptional activity. Inactivation of *Sox7* could promote the development of a majority of colorectal tumors and approximately half of prostate tumors.

Keywords

WNT signaling; promoter methylation; tumor suppressor; chromosome 8p; Sox7; prostate cancer; colorectal cancer; β-catenin

Request for reprints: Wei Zhou, Winship Cancer Institute of Emory University, Building C, Room 4084, 1365 Clifton Road, NE, Atlanta, GA 30322. Phone: (404) 778-2134; FAX: (404) 778-5530; Email: wei.zhou@emoryhealthcare.org.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Introduction

Aberrant activation of the 'canonical' WNT signaling plays an important role in the development of colorectal cancer (1). The central player in this signaling cascade is a cytoplasmic protein called β-catenin. The stability of β-catenin is regulated by a multi-component cytoplasmic destruction complex containing APC, axin and glycogen synthase kinase 3 β (GSK3β) (2). In the absence of WNT signaling, these proteins bind to β-catenin in the cytosol and promote its phosphorylation, which eventually triggers its degradation. In colorectal cancers, mutational inactivations of the *APC/axin* genes or mutational activations of the *β-catenin* gene disrupt the interaction between β-catenin and this cytoplasmic destruction complex, leading to the stabilization of β-catenin in the nucleus (1). Nuclear β-catenin interacts with T-cell factor (TCF)/lymphoid enhancer factor (LEF) and activates transcription that has been termed CRT (β-catenin/TCF regulated transcription). Activations of CRT target genes, such as *c-myc* and *cyclin D1*, are now believed to be responsible for carcinogenesis of the colon (3).

Several lines of evidence in humans and animal models also indicate that aberrant activation of β-catenin plays a role in the development of prostate cancer. First, studies in transgenic mice show that mutational activation of *β-catenin* in the germline leads to nuclear stabilization of β-catenin and to hyperplasia, thereby suggesting that aberrant activation of β-catenin is responsible for the increased cell proliferation (4,5). More importantly, in one mutant β-catenin mouse model, lesions are formed in the prostatic lobes that are reminiscent of high grade prostatic intraepithelial neoplasia (PIN), a precursor for prostate cancer (5). Second, when nuclear β-catenin staining by immunohistochemistry is used as a surrogate marker for the activation of WNT/β-catenin signaling, it is detected in ~20% of advanced prostate cancer tissues, but not in normal prostate epithelial cells (6). Third, somatic mutations of the *β-catenin* gene that could lead to stabilization of the β-catenin protein in the nucleus have been identified in only 5% of prostate cancers (7). Indeed, the molecular basis of aberrant stabilizations of β-catenin in the majority of prostate cancer cases is not due to defects in the β-catenin or even the multi-component destruction complexes, as mutational alterations of β-catenin or of other known components of the destruction complexes are rare in prostate cancer cells (8,9). Consequently, an important question regarding β-catenin function in prostate cancer is whether β-catenin is negatively regulated by another protein.

The short arm of chromosome 8 (8p) is one of the most frequently deleted regions in prostate cancer (10–15). Several studies indicate that chromosome 8p may contain several tumor suppressors that play different roles in the development of prostate cancer (13,16). Linkage analyses in families with hereditary prostate cancer support this concept. A recent analysis of 206 families with hereditary prostate cancer reveals two separate linkage peaks, at 8p21.3 (LOD score = 2.51, p=0.0007; NPL score = 3.14) and 8p23.1 (LOD score = 1.50, p=0.009; NPL score = 2.72) (17). In the same study, somatic deletion analysis performed on 55 prostate tumors identifies a 3.1 Mb region at 8p21.3 and a 1.4 Mb region at 8p23.1. The 8p21.3 region contains 37 known genes, including the putative tumor suppressor gene NKX3.1. In contrast, the 8p23.1 region is only 1.4 Mb in length and contains 5 known genes. This region covers the entire promoter and the coding regions of *Sox7*. A previous report showed that a shared sequence motif between Sox17 and Sox7 mediates Sox17's interaction with β-catenin (18). Hence, in this study we investigated the role of the Sox7 protein in WNT signaling in prostate and colorectal cancer, and evaluated the frequency of *Sox7* inactivation in prostate cancer.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Results

Down-regulation of Sox7 protein and mRNA expression in primary prostate tumors

Immunohistochemistry (IHC) was used to evaluate Sox7 protein expression in archived paraffin-embedded specimens. In all eight normal prostates examined, Sox7 protein was present and was mostly cytoplasmic. In contrast, in 32 cases of prostate adenocarcinomas, we found Sox7 expression was significantly down-regulated in 15 cases (47%). Sox7 protein was detected in 17 of the prostate adenocarcinoma cases (53%). In addition to cytoplasmic staining, membranous staining of Sox7 protein was detected in one case. Some of these cases contained paired tumor/normal specimens from the same individual. Two examples are shown in Figure 1A, to illustrate the tumor-specific down-regulation of Sox7 expression in autologous tissues.

Next, quantitative real-time PCR (qPCR) was used to evaluate *Sox7* mRNA expression levels in nine paired fresh/frozen prostate specimens. In most normal prostate samples, *Sox7* was expressed at similar levels, with the exception of sample I, in which *Sox7* expression was not detectable (Figure 1B). In contrast, *Sox7* expression was undetectable in 67% (6 out of 9) of the adjacent primary prostate tumor tissues (Figure 1B, cases A–F).

Tumor-specific promoter hypermethylation of Sox7 in prostate cancers

Methylation-specific PCR (MSP) was used to determine the promoter methylation status of the *Sox7* gene in 21 paraffin-embedded primary prostate cancer tissue specimens. MSP primers were designed to interrogate the methylation status of CpG sites overlapping Exon 1 and the CpG island of *Sox7* (Figure 2A). Genomic DNA was microdissected from both tumor cells and adjacent normal tissues, then treated with sodium bisulfite. DNA isolated from normal human epithelial cells was used as an unmethylated control (Figure 2B, lanes 3–4), and normal DNA methylated *in vitro* with SssI (CpG) Methylase was used as a methylated control (Figure 2B, lanes 1–2, IVD). In our MSP analysis, tumor-specific *Sox7* promoter methylation was detected in 10 out of 21 (48%) primary prostate tumors (Figure 2B). Promoter hypermethylation status was also confirmed in cases #1 through #4, by bisulfite sequencing (BSS, Figure 2C). In our MSP analysis, *Sox7* promoter hypermethylation was also detected in three normal prostate samples. In case #8, *Sox7* promoter methylation was observed in both tumor and normal tissues. Cases #10 and #12 had *Sox7* promoter methylation only in their normal tissues. Hence, a small percentage of prostate cancer patients had *Sox7* promoter methylation in apparently normal prostate epithelium.

We also determined the chromosome 8p allelic status for the same panel of prostate tumors using "counting alleles," a method we had previously developed to analyze allelic imbalance in archived specimens having single nucleotide polymorphisms (19). A panel of nine SNP markers (NCBI RefSNP numbers 1124, 3185, 3850751, 3888179, 3258, 11362, 3112, 532841, and 14879 from 8p21.2 to 8p23.2) were used to evaluate allelic imbalance in these tumors. Three of the tumors did not have any informative markers in this panel, so their 8p allelic status could not be determined. Of the remaining 18 tumors, eleven (61%) tumors contained allelic loss in at least one SNP marker in this region. This result was similar to our previous finding, where 8p allelic imbalance was detected in 64% of prostate cancers (20). It is of note that Sox7 promoter methylation was detected in 64% (7/11) of prostate tumors with 8p allelic imbalance, but only in 29% (2/5) of prostate tumors without 8p allelic imbalance. Even though the sample size was limited, this trend suggests that promoter hypermethylation frequently occurs in combination with LOH, thereby functionally inactivating both alleles of *Sox7* in prostate tumors.

We also carried out MSP analysis in a panel of prostate cancer cell lines and xenografts. *Sox7* promoter methylation was detected in 11 out of 25 (44%) samples (Table 1). The

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

expression level of *Sox7* mRNA was verified by qPCR, which detected *Sox7* expression in DU145 and PC-3 cells, plus the normal human prostate epithelial cell line PrEC, and revealed a significant down-regulation of *Sox7* expression in both the LNCaP and 22Rv1 cell lines (Figure 3A). BSS identified promoter methylation in LNCaP, 22Rv1, and CRW22, but not in DU 145 as expected (Figure 3B). The *Sox7* mRNA expression level also correlates with the level of Sox7 protein.Sox7 protein was detected in DU 145 and PC-3 cells, but not LNCaP or 22Rv1 cells, by Western analysis (Figure 6C and supplemental figure 1). However, an examination of the coding sequence of the Sox7 gene did not reveal any nonsense or missense mutations in seven CaP cancer cell lines (22Rv1, LNCaP, PC-3, DU 145, NCI-660, BRT41T and PC82).

We also investigated whether demethylation of the *Sox7* promoter could restore *Sox7* expression in LNCaP cells. Both DU145 and LNCaP cells were treated with 0.5 μM 5-aza-2'-deoxycytidine (5AZ). Then the expression of *Sox7* mRNA was determined by qPCR, and the promoter methylation status in LNCaP cells was validated by MSP. We found that in LNCaP cells, 5AZ treatment led to demethylation of the Sox7 promoter (Figure 3D) and stimulation of *Sox7* expression by more than 250-fold (Figure 3C). In contrast, 5AZ treatment had little effect on *Sox7* mRNA expression in DU145 cells, which do not contain *Sox7* promoter methylation. Therefore, we have clear proof that *Sox7* expression can be restored in LNCaP cells by chemical demethylation of the *Sox7* promoter.

Sox7 binds to β-catenin, depletes active β-catenin, and inhibits CRT

Sox7 was previously shown to be able to suppress β-catenin/T-cell factor (TCF)-regulated transcription (CRT) (21). We analyzed the inhibitory effect of Sox7 on transiently stimulated CRT by β-catenin and the pOT-Flash reporter plasmid in H1299 cells (22). The pOT-Flash plasmid contains three TCF/β-catenin binding sites upstream of a minimal promoter and the firefly luciferase reporter gene. The same plasmid, but with the binding sites mutated (pOF-Flash), was used as a negative control. A *Renilla* luciferase control reporter (pRL-CMV) was included in all experiments, to normalize transfection efficiency. As expected, co-transfection of the β-catenin plasmid with pOT-Flash, but not with pOF-Flash, led to activation of firefly luciferase expression (Figure 4B). Transfection of Sox7 (CMV-Tag2/Sox7) alone had no effect on basal transcription from the pOT-Flash or the pOF-Flash reporters. However, wild-type Sox7 did suppress CRT in a dose-dependent manner in the presence of β-catenin expression, and a 77% inhibition of CRT activity was achieved the highest dose of Sox7 in H1299 cells (Figure 4B).

The Sox7 protein contains a DxxEFDQYL motif that is evolutionary conserved and that may mediate Sox7’s interaction with β-catenin (18). Therefore, we generated a Sox7 deletion construct, Sox7-Δ (DRN-----S), removing this putative β-catenin interaction motif in order to discover its true function (Figure 4A). We first determined whether Sox7 physically interacts with the β-catenin protein through this putative β-catenin binding motif, by transfecting HEK293 cells with a Flag-tagged Sox7 expression plasmid (CMV-Tag2/Sox7) and a construct expressing β-catenin (23). Indeed, β-catenin protein was detected in immuno-precipitated complexes with Sox7 (Figure 4C, lane 2), indicating that Sox7 is capable of binding to β-catenin. In addition, β-catenin was not detected in cells transfected with Sox7-Δ, suggesting that the EFDQY residues within the newly confirmed β-catenin binding motif were necessary for Sox7 to bind to β-catenin (Figure 4C, lane 1). A Sox7 mutant construct that only retained the DxxEF structure (Figure 4A, Sox7-M, DRNEFGGG) was still capable of binding to β-catenin (Figure 4C, lane 3), implying that the glutamic acid (E) and phenylalanine (F) within this motif might play significant roles in the binding process.

We also evaluated whether Sox7-Δ is still capable of suppression β-catenin-mediated CRT in H1299 cells. Low dose of Sox7-Δ (32 ng of plasmid) achieved similar level of CRT inhibition

(27% inhibition) as equivalent amount wild type Sox7 (24% inhibition). Unlike wild-type Sox7, increased dose of Sox7-Δ did not result in further CRT inhibition because of a significant increase in the transcription of pOF-Flash plasmid by Sox7-Δ (Figure 4B). Therefore, the β-catenin interaction motif of Sox7 is required for Sox7 to specifically suppress β-catenin-mediated transcription.

Because WNT signals specifically increase a subpopulation of β-catenin protein that is dephosphorylated at residues Ser37 and Thr41, dephosphorylated β-catenin is thought to be the active form of β-catenin that participates in CRT (24). We next evaluated the level of active β-catenin protein after ectopic Sox7 expression. Sox7 or Sox-Δ was co-expressed with a S33Y mutant β-catenin in 293 cells. S33Y β-catenin mutation was initially identified in SW48 colorectal cancer cell line, and this mutant is resistant to APC mediated degradation (1). The expression level of β-catenin protein was similar in cells transfected with either Sox7 or Sox-Δ when a polyclonal anti-β-catenin antibody was used in the analysis (Figure 4D, middle-left panel, lanes 1 and 2). However, cells transfected with Sox7 had a significant decrease in active β-catenin compared to ones transfected with Sox7-Δ (Figure 4D, top-left panel, lanes 1 and 2), suggesting that ectopic expression of Sox7 specifically depletes active β-catenin and this depletion requires the interaction between Sox7 and β-catenin. In addition, MG132 treatment was capable of blocking Sox7-mediated depletion of active β-catenin (Figure 4D, top-left panel, lanes 1 and 3), implying that the depletion of active β-catenin is mediated by proteasome degradation. The depletion of active, but not total β-catenin, by ectopic Sox7 expression was also observed in COS-7 cells (Figure 4D, right panel). In summary, this data suggest that ectopic expression of Sox7 mediates the degradation of active β-catenin in an APC-independent mechanism.

Sox7 inactivation in colorectal cancers

Since Sox7 is capable of inhibiting CRT, it may act as an independent checkpoint to control β-catenin activity. If this is the case, the inactivation of Sox7 function would be necessary for developing colorectal cancer, because it is known that aberrant WNT/β-catenin signaling plays a critical role in colorectal cancer development (1). We first determined the promoter methylation status of the *Sox7* gene in HCT116 (a colorectal cancer cell line with a *β-catenin* mutation) and HT29 (a colorectal cancer cell line with an *APC* mutation) (1,22), finding that the *Sox7* promoter was heavily methylated in both cell lines (Figure 5A). The activating *β-catenin* mutation in HCT116 is a 3-bp deletion that eliminated the serine residue at codon 45 (1). This mutation disrupts β-catenin's interaction with the cytoplasmic destruction complex (22), and CRT can be detected in HCT116 with transient transfection of the pOT-Flash plasm id alone (Figure 5B). Ectopic expression of wild-type Sox7; however, inhibited the aberrant CRT activity mediated by this mutant β-catenin, suggesting that this mutation was not sufficient to alleviate Sox7 suppression.

Our data in HCT116 cells suggests that disruption of the Sox7/β-catenin interaction may be an additional requirement in the carcinogenesis of colon. To investigate this possibility, we evaluated the *Sox7* promoter methylation status of colorectal primary tumors. MSP was performed using genomic DNA isolated from eight snap-frozen, paired tissues from tumor and adjacent normal specimens from colorectal cancer patients. In this tissue type, *Sox7* promoter methylation was detected in 100% (6/6) of the tumors, but not in any adjacent normal tissues, by MSP analysis (Figure 5C). We failed to amplify the correct size PCR product from tumor DNA after repeated attempts, as well as with MSP primer sets #1 or #2 for the remaining two samples. Nevertheless, this experimental data indicated that the *Sox7* gene is inactivated by tumor-specific promoter methylation in a majority of colorectal primary tumors.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

NIH-PA Author Manuscript

Transient and Tet-inducible Sox7 expression inhibits cell proliferation

To investigate the effect of Sox7 expression on cell proliferation in Sox7-null cells, a CMV-Tag2/Sox7 expression plasmid was transfected into LNCaP, 22Rv1 and HCT116 colon cancer cells. Following G418 selection, there was a significant reduction in colony formation after transfection with the Sox7 expression vector as compared to the empty vector control (CMV-Tag2, Figure 6A & B), indicating that transfected function of ectopic expression of Sox7 inhibited cell proliferation. As the transient transfection rate was low in the CaP cell lines, we also developed stable cell lines for the inducible expression of Sox7. C4-2 is a prostate cancer cell line derived from LNCaP (25). A Flag-tagged mouse *Sox7* was cloned into pTRE2 and transfected into Tet-inducible C4-2 cells. Following isolation of two stable clones, the removal of Dox from their culture media was able to induce Sox7 protein expression after 48 hours (two examples, Figure 6C). Similar to the transient transfection analysis, implementation of a colony formation assay for these two stable cell lines revealed significant reductions in cell proliferation in the absence of Dox, i.e. in colonies having Sox7 expression (Figure 6D). Therefore, ectopic expression of Sox7 in Sox7-null cells inhibits or greatly reduces cell proliferation.

Discussion

Allelic loss of chromosome 8p is one of the most frequently observed somatic genetic alterations in human cancers (26–29). The inactivation of a putative tumor suppressor gene in this region is thought to be the reason for this loss, as tumor suppressor inactivation would be essential for carcinogenesis to occur. In 1989, this 8p allelic loss was initially observed by Vogelstein et al. in colorectal cancer (30). However, despite rigorous efforts by various research groups over the past eighteen years, the identity of the putative tumor suppressor in 8p remained unknown. Somatic deletion analyses of chromosome 8p indicate that this region may even contain several tumor suppressor genes, in the case of prostate carcinogenesis (13,16). Although *NKX3.1* is a promising candidate at 8p21.3 (31,32), so far it has only been implicated in prostate cancer (33,34). Two linkage analyses of hereditary prostate cancers predict that there is another prostate cancer susceptibility locus at 8p22–23 (35,36), plus a recent analysis by Chang et al. resolves two different linkage peaks at 8p21.3 and 8p23.1(17). In the same study, somatic deletion analysis refines the 8p23.1 locus to a 1.4 Mb region holding only five candidate genes, including *Sox7* (17).

Our laboratory first worked to characterize Sox7 protein expression by using an antibody from R&D system that is suitable for both immunohistochemistry (Figure 1) and immunoblot analysis (Supplemental Figure 1). An immunohistochemistry analysis revealed that Sox7 protein expression is down-regulated in around 47% of prostate adenocarcinomas. Our analyses in prostate cancer cell lines and xenografts indicated that the observed down-regulation of Sox7 protein expression may be due to *Sox7* promoter hypermethylation, which is detected in 44% of these samples. Most importantly, we demonstrated that there was tumor-specific inactivation of *Sox7* by promoter hypermethylation in 48% of the primary prostate tumors tested. Of those prostate tumors with *Sox7* promoter hypermethylation, 78% (7/9) also contained a chromosome 8p allelic imbalance, suggesting that promoter hypermethylation in combination with allelic loss may be responsible for the inactivation of both *Sox7* alleles in a significant portion of prostate tumors. The combination of results from the linkage analyses and our study of the tumor-specific inactivation of *Sox7* strongly suggest that Sox7 is indeed a candidate tumor suppressor gene, located at 8p23.1.

The *Sox7* gene encodes a transcription factor that can both enhance and inhibit transcription (21). It has been found to be essential for cardiogenesis in *Xenopus* (37) and it is known to be involved in the transcriptional regulation of several differentiation-related genes (18,23,38). One of over 26 members of the Sox protein family, Sox7 is a member of the SoxF subfamily

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

of proteins, which also includes Sox17 and Sox18 (39). In fact, Sox7 shares several homologous motifs with Sox17 and Sox18. One of these motifs enables Sox17 to bind to β-catenin and inhibit CRT in *Xenopus* (40). Because all the SoxF proteins contain this purported β-catenin interaction motif, all of them may potentially inhibit CRT. In this study, we demonstrated that Sox7 interacts with β-catenin, and such interaction mediates the degradation of active β-catenin, which results in the suppression of CRT. In addition, we showed that ectopic expression of Sox7 in Sox7-null cells inhibits cell proliferation. The ability of Sox7 to negatively regulate CRT and inhibit cell proliferation is consistent with a role as a tumor suppressor. This information could be of use for future diagnosis and targeted therapy of prostate tumors.

We then wondered if Sox7 serves as an independent checkpoint for β-catenin function. It is known that aberrant WNT signaling plays an essential role in the initiation of colorectal cancer (3), and that the majority of colorectal cancers contain mutations in either β-catenin or the cytoplasmic destruction complex, both of which result in the stabilization of nuclear β-catenin and tumor growth (2). Emerging evidence indicates that other proteins, such as the SFRPs which inhibit the WNT receptor, are also capable of attenuating WNT signaling even in the presence of down-stream mutations (41). Despite these advances in understanding the relationship between catenin, WNT signaling, and tumor growth, our current understanding of β-catenin regulation remained limited to the existence of control via the cytoplasmic destruction complex, even though Zorn et al. had demonstrated back in 1999 that β-catenin function could be inhibited by Sox17, at least in *Xenopus* (40). The Zorn data proved to be a valuable clue to uncovering Sox7 functionality in human cells. Our data indicate that *Sox7* is inactivated in the HCT116 human colorectal cancer cell line and that ectopic Sox7 expression can suppress CRT activated by an endogenous mutant β-catenin. As Sox7 is capable of inhibiting WNT signaling even in the presence of a β-catenin mutation, the inhibition of sox7 expression may be as important as disrupting the β-catenin/cytoplasmic destruction complex interaction in colorectal cancers. Indeed, our preliminary analysis of a panel of primary colorectal tumors indicates that tumor-specific promoter hypermethylation of *Sox7* is present in most colorectal primary tumors, in a manner quite similar to what was found for about half of the prostate cancers tested. These data is consistent with our observation that Sox7 mediates the degradation of active S33Y β-catenin via an APC-independent mechanism (Figure 4D). Therefore, it is our conclusion that the *Sox7* gene most likely encodes a candidate tumor suppressor that plays an important role in suppressing various cancers, and one of Sox7 functions is to serve as an independent checkpoint for β-catenin transcriptional activity.

The function of Sox7 may not be limited to the regulation of β-catenin transcriptional activity because the over-expression of Sox7 lacking the β-catenin binding domain retains some inhibitory activity in colony formation assay (Zhong et al unpublished observations). The growth of prostate cancer cells can be stimulated by androgen (42), and some Sox proteins are involved in the regulation of androgen receptor expression in prostate cancer cells (43). In our study, Sox7 expression was not detected in androgen-dependent LNCaP cell line, and it will be interesting to determine in the future whether the expression of Sox7 in LNCaP cells interferes with androgen-dependent cell growth.

Materials and Methods

Materials

Rabbit polyclonal anti-Sox7 antibody was purchased from R&D systems for immunohistochemistry analysis (cat#AF2766). Rabbit polyclonal anti-Sox7 (H175) antibody (sc-20093) was purchased from Santa Cruz Biotechnology Inc for immunoblot analysis. Rabbit polyclonal anti-b-catenin antibody (cat#9587) was purchased from Cell Signaling Technology (Danvers, MICROARRAY), and anti-Active-β-catenin (anti-ABC, clone 8E7) antibody was

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

purchased form Millipore. Rabbit polyclonal anti-actin antibody was purchased from Sigma Chemical Co. (St. Louis, MO). The primary tumors from human prostate and colon tissues were collected previously (20,44). Genomic DNA and RNA were extracted as described previously (45). The pCMV-Tag2/Sox7 expression plasmid was provided by Dr. Akira Murakami (23), while the pOT-Flash, pOF-Flash, and wild type and S33Y β-catenin expression constructs were obtained from Dr. Bert Vogelstein (1,22).

Cell culture and demethylation treatment

Prostate cancer cell lines (PC-3, DU 145, LNCaP, and 22RV1), HEK-293 cell line, non-small cell lung cancer cell line (H1299), and colorectal cancer cell line (HCT116) were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and propagated according to the conditions recommended by ATCC. To demethylate the hypermethylated Sox7 promoter, both LNCaP and DU 145 cells were treated with 2 uM 5-aza-2'-deoxycidine for 72 h, as has been previously described (46).

Immunohistochemistry for Sox7

The formalin-fixed, paraffin-embedded tissue microarrays of prostate and colorectal primary tumors were purchased from US Biomax, Inc. These tissue arrays were immunostained for Sox7 (AF2766, 1:50 dilution, goat polyclonal antibody, R&D systems) following heat-induced antigen retrieval, then developed using horseradish peroxidase (HRP)-labeled polymer and the DAKO Autostainer Staining System (Dako Corp, Carpinteria, CA), as described previously (45). Quantitation in IHC was based on scoring for the number of positively-stained cells, but not the intensity of staining. Scores ranged from 0 to 3+, and any samples with 2–3+ as an IHC score were defined as having normal levels of Sox7 expression.

Quantitative real-time RT-PCR analysis

Total RNA was isolated from snap-frozen primary tumors as described previously (47). This total RNA was reverse transcribed to cDNA, and qPCR was carried out in a 20-μl volume using iQ SYBR green supermix (Bio-Rad, cat# 170-8882) on a Bio-Rad iCycler. Primer sequences for RT-PCR and qPCR of *Sox7* are listed in Supplemental Table 1. A similar analysis was carried out for *GAPDH*, then the relative *Sox7* expression levels were determined by comparing the threshold cycle values of *Sox7* to *GAPDH* (45).

Methylation analysis

Bisulfite modification of genomic DNA followed by PCR amplification was carried out as described previously (46). For bisulfite sequencing, genomic DNA was amplified using primers that were not specific for methylation status. Primer sequences for MSP and bisulfite sequencing PCR are listed in Supplemental Table 1.

Allelic imbalance analysis

Tissue specimens were manually microdissected, then the tumor DNA was isolated from tissue samples as previously described (20). DNA from adjacent benign prostate epithelia was also isolated for use as the autologous normal control. First, the normal DNA samples were genotyped for chromosome 8p (ch8p) heterozygosity using nine bi-allelic single-nucleotide polymorphic markers (SNPs) on chromosome 8p, to select for an informative marker for subsequent allelic imbalance analysis. These SNP markers (NCBI RefSNP numbers: 1124, 3185, 3850751, 3888179, 3258, 11362, 3112, 532841, and 14879) are located from 8p21.2 to 8p23.2 on the cytogenetic band. The allelic status of 8p was determined using a combination of digital SNP and sequential probability ratio tests, as previously described (19).

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Luciferase reporter assay

Cells were plated at 5×10^4 cells per well on 24-well tissue culture plates, 24 h before transfection. All transfections were carried out with lipofectamine 2000 (invitrogene) and pRL-CMV. Luciferase activity was measured in a luminometer (BD Biosciences) after 48 h, and the resulting data were normalized for the background *Renilla* luciferase activity using the Dual Luciferase Reporter Assay system (Promega). For the CRT assay, each well was transfected with 100 ng pOT-Flash, a TCF-LEF-responsive reporter, or 100 ng pOF-Flash, a negative control with a mutated TCF-LEF binding site; indicated amount of pCMV-Tag2B/Sox7, pCMV-Tag2B/Sox7-Δ, or pCMV-Tag2B.

Immuno-coprecipitation and immunoblot

HEK293 cells were plated at 1×10^6 cells on 10 cm tissue culture dish 24 hour before transfection. All transfections were carried out with lipofectamine 2000 (invitrogene) and indicated plasmid constructs. Cell lysates were harvested 48 hours after transfection, and immuno-precipitated with anti-Flag M2-Agarose from mouse (cat#A2220-5ML, Sigma-Aldrich, Inc, St. Louis, MO). For immunoblot analysis, cell lysates or immuno-precipiated complexes were separated by SDS-PAGE and blotted onto PDVM membrane. Antibodies against Sox7 and β-catenin were used for immunoblot analysis.

For the analysis of active-β-catenin in HEK293, cells were transfected with 0.5 μg pCMV-S33Y-β-catenin and 0.5 μg pCMV-Tag2B/Sox7 or pCMV-Tag2B/Sox7-Δ plasmids. For similar analysis in COS-7 cells, cells were transfected with 0.5 μg pCMV-S33Y-β-catenin and 0.5 μg pCMV-Tag2B or pCMV-Tag2B/Sox7 plasmids. Cell lysates were harvested 48 hours after transfection. For MG-132 blocking experiment, 20 μM MG-132 was added to the culture 4 hours before the collection of culture media. Antibodies against active β-catenin, β-catenin, FLAG and actin were used for immunoblot analysis.

Colony formation assay

Cells were transfected with pCMV-Tag2B/Sox7 or an empty vector control, using lipofectamine 2000. At 24 h after transfection, these cells were trypsinized and plated onto 6-well plates, then selected for 14 days with 1 μg/ml geneticin (Invitrogen).

Generation of a stable Tet-inducible cell line

The “Tet-inducible” C4-2 cell line was a generous gift from Dr. Leland Chung at Emory University. Briefly, a Flag-tagged mouse *Sox7* was cloned into pTRE2 and transfected into the “Tet-inducible” C4-2. Cells were selected in culture media containing puromycin. Two double-stable clones were isolated 14 days after selection began. The incorporation of pTRE2-Sox7 into the cell line was validated by genomic PCR amplification of mouse specific PCR primers: Sox7-SF (5’-TTTTTATTTGTATATTTTGGTGTAGAT-3’) and Sox7-SR (5’-CTCACTCATTCTACAAACCTTAAAC-3’). Induction of mouse Sox7 mRNA in the absence of Doxycycline was also confirmed by quantitative real-time RT-PCR using GAPDH as an internal control.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We thank Dr. Bert Vogelstein for providing pOT-Flash, pOF-Flash, β-catenin expression constructs, Dr. Akira Murakami for providing pCMV-Tag2/Sox7 expression plasmid, and Dr. Leland Chung for providing C4-2/Tet-off cell line. We thank Kathleen Kite-Powell for manuscript editing.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Grant support: American Cancer Society RSG-05-038-01-CCE (W. Zhou), Department of Defense W81XWH-05-1-0042 (W. Zhou), and Georgia Cancer Coalition Distinguished Cancer Scholar Award (W. Zhou).

References

1. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997 Mar 21;275(5307):1787–1790. [PubMed: 9065402]
2. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006 Nov 3;127(3):469–480. [PubMed: 17081971]
3. Morin PJ. beta-catenin signaling and cancer. Bioessays 1999 Dec;21(12):1021–1030. [PubMed: 10580987]
4. Bierie B, Nozawa M, Renou JP, et al. Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 2003 Jun 19;22(25):3875–3887. [PubMed: 12813461]
5. Gounari F, Signoretti S, Bronson R, et al. Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 2002 Jun 13;21(26):4099–4107. [PubMed: 12037666]
6. Chesire DR, Isaacs WB. Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. Oncogene 2002 Dec 5;21(55):8453–8469. [PubMed: 12466965]
7. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000 Dec 1;45(4):323–334. [PubMed: 11102958]
8. Chesire DR, Isaacs WB. Beta-catenin signaling in prostate cancer: an early perspective. Endocr Relat Cancer 2003 Dec;10(4):537–560. [PubMed: 14713266]
9. Gerstein AV, Almeida TA, Zhao G, et al. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 2002 May;34(1):9–16. [PubMed: 11921277]
10. Emmert-Buck MR, Vocke CD, Pozzatti RO, et al. Allelic loss on chromosome 8p12–21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 1995 Jul 15;55(14):2959–2962. [PubMed: 7606709]
11. Macoska JA, Trybus TM, Sakr WA, et al. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res 1994;54(14):3824–3830. [PubMed: 8033102]
12. Matsuyama H, Pan Y, Skoog L, et al. Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization. Oncogene 1994 Oct 9;(10):3071–3076. [PubMed: 8084616]
13. Oba K, Matsuyama H, Yoshihiro S, et al. Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer. Cancer Genet Cytogenet 2001;124(1):20–26. [PubMed: 11165318]
14. Qian J, Jenkins RB, Bostwick DG. Determination of gene and chromosome dosage in prostatic intraepithelial neoplasia and carcinoma. Anal Quant Cytol Histol 1998;20(5):373–380. [PubMed: 9801755]
15. Vocke CD, Pozzatti RO, Bostwick DG, et al. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12–21. Cancer Res 1996;56(10):2411–2416. [PubMed: 8625320]
16. Perinchery G, Bukurov N, Nakajima K, et al. Loss of two new loci on chromosome 8 (8p23 and 8q12–13) in human prostate cancer. Int J Oncol 1999;14(3):495–500. [PubMed: 10024682]
17. Chang BL, Liu W, Sun J, et al. Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p. Cancer Res 2007 May 1;67(9):4098–4103. [PubMed: 17483320]
18. Sinner D, Rankin S, Lee M, Zorn AM. Sox17 and beta-catenin cooperate to regulate the transcription of endodermal genes. Development 2004 Jul;(13):3069–3080. [PubMed: 15163629]
19. Zhou W, Galizia G, Lieto E, et al. Counting alleles reveals a connection between chromosome 18q loss and vascular invasion. Nat Biotechnol 2001 Jan;19(1):78–81. [PubMed: 11135558]
20. Zhou W, Goodman M, Lyles RH, et al. Surgical margin and Gleason score as predictors of postoperative recurrence in prostate cancer with or without chromosome 8p allelic imbalance. Prostate 2004 Sep 15;61(1):81–91. [PubMed: 15287096]

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

21. Takash W, Canizares J, Bonneaud N, et al. SOX7 transcription factor: sequence, chromosomal localisation, expression, transactivation and interference with Wnt signalling. Nucleic Acids Res 2001 Nov 1;29(21):4274–4283. [PubMed: 11691915]
22. Chan TA, Wang Z, Dang LH, Vogelstein B, Kinzler KW. Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc Natl Acad Sci U S A 2002 Jun 11;99(12):8265–8270. [PubMed: 12060769]
23. Murakami A, Shen H, Ishida S, Dickson C. SOX7 and GATA-4 are competitive activators of Fgf-3 transcription. J Biol Chem 2004 Jul 2;279(27):28564–28573. [PubMed: 15082719]
24. Staal FJ, Noort Mv M, Strous GJ, Clevers HC. Wnt signals are transmitted through N-terminally dephosphorylated beta-catenin. EMBO Rep 2002 Jan;3(1):63–68. [PubMed: 11751573]
25. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994 May 15;54(10):2577–2581. [PubMed: 8168083]
26. Anbazhagan R, Fujii H, Gabrielson E. Allelic loss of chromosomal arm 8p in breast cancer progression. Am J Pathol 1998 Mar;152(3):815–819. [PubMed: 9502423]
27. Takle LA, Knowles MA. Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene 1996;12(5):1083–1087. [PubMed: 8649800]
28. Chang M, Tsuchiya K, Batchelor RH, et al. Deletion mapping of chromosome 8p in colorectal carcinoma and dysplasia arising in ulcerative colitis, prostatic carcinoma, and malignant fibrous histiocytomas. Am J Pathol 1994;144(1):1–6. [PubMed: 8291601]
29. Bova GS, Carter BS, Bussemakers MJ, et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993;53(17):3869–3873. [PubMed: 7689419]
30. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science 1989 Apr 14;244(4901):207–211. [PubMed: 2565047]
31. He WW, Sciavolino PJ, Wing J, et al. A novel human prostate-specific, androgen regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997 Jul 1;43(1):69–77. [PubMed: 9226374]
32. Kim MJ, Cardiff RD, Desai N, et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A 2002 Mar 5;99(5):2884–2889. [PubMed: 11854455]
33. Lei Q, Jiao J, Xin L, et al. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 2006 May;9(5):367–378. [PubMed: 16697957]
34. Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C. Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res 2005 Aug 1;65(15):6773–6779. [PubMed: 16061659]
35. Xu J, Zheng SL, Hawkins GA, et al. Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22–23. Am J Hum Genet 2001 Aug;69(2):341–350. [PubMed: 11443539]
36. Wiklund F, Jonsson BA, Goransson I, Bergh A, Gronberg H. Linkage analysis of prostate cancer susceptibility: confirmation of linkage at 8p22–23. Hum Genet 2003 Apr;112(4):414–418. [PubMed: 12594535]
37. Zhang C, Basta T, Klymkowsky MW. SOX7 and SOX18 are essential for cardiogenesis in Xenopus. Dev Dyn 2005 Dec;234(4):878–891. [PubMed: 16193513]
38. Futaki S, Hayashi Y, Emoto T, Weber CN, Sekiguchi K. Sox7 plays crucial roles in parietal endoderm differentiation in F9 embryonal carcinoma cells through regulating Gata-4 and Gata-6 expression. Mol Cell Biol 2004 Dec;24(23):10492–10503. [PubMed: 15542856]
39. Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol 2000 Nov 15;227(2):239–255. [PubMed: 11071752]
40. Zorn AM, Barish GD, Williams BO, Lavender P, Klymkowsky MW, Varmus HE. Regulation of Wnt signaling by Sox proteins: XSox17 alpha/beta and XSox3 physically interact with beta-catenin. Mol Cell 1999 Oct;4(4):487–498. [PubMed: 10549281]
41. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004 Apr;36(4):417–422. [PubMed: 15034581]

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

42. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004 Apr;25(2):276–308. [PubMed: 15082523]

43. Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res 2007 Jan 15;67(2):528–536. [PubMed: 17234760]

44. Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE, Yang VW. Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene 2004 Jan 15;23(2): 395–402. [PubMed: 14724568]

45. Zhong D, Guo L, de Aguirre I, et al. LKB1 mutation in large cell carcinoma of the lung. Lung Cancer 2006 Sep;53(3):285–294. [PubMed: 16822578]

46. Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 2000 Nov 15;60(22):6236–6242. [PubMed: 11103776]

47. Liu P, Ramachandran S, Ali Seyed M, et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006 Apr 15;66(8):4011–4019. [PubMed: 16618720]

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript



Figure 1. Sox7 protein and mRNA expression analyses in primary prostate tumors

A. Immunohistochemical analysis of Sox7 expression in two examples of paired prostate tumors with adjacent normal tissues. N: normal prostate; T: prostate tumor; a–b: case numbers. **B**. Expression of *Sox7* mRNA in paired prostate tumor and normal tissues. *Sox7* mRNA expression was measured by qPCR using *GAPDH* as internal control. Reactions were carried out in triplicate. Arrow bar represents one standard deviation. Filled bars: tumor; open bars: adjacent normal prostate.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript



Figure 2. Tumor-specific promoter hypermethylation of *Sox7* in primary prostate tumors

A. Genomic structure of the *Sox7* promoter. Shaded region indicates CpG islands and arrow indicates the direction of transcription. Tel: telomere; Cent: centromere; E1: exon 1, MSP: methylation-specific PCR product, BSS: bisulfite sequencing product. **B**. MSP analysis of the *Sox7* promoter and chromosome 8p allelic imbalance analysis in primary prostate tumors. For the MSP analysis, genomic DNA isolated from macro-dissected prostate primary tumors and adjacent normal tissues was treated with bisulfite and amplified using MSP primers. Samples with tumor-specific methylation are denoted with *. IVD: *in vitro* methylated control DNA. For 8p allelic imbalance analysis, genomic DNA was used for "counting alleles" analysis. AI: tumors with 8p allelic imbalance; R: tumors retaining both parental alleles; NI: samples with no informative SNP markers. **C**. Bisulfite-treated genomic DNA was amplified with BSS primers. BSS PCR products were subcloned and individual subclones were isolated and

sequenced. Open and filled circles represent unmethylated and methylated CpG sites, respectively, and each row represents a single clone.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript



Figure 3. Sox7 expression in prostate cancer cell lines

A Expression of *Sox7* mRNA in prostate cancer cell lines was measured by qPCR using *GAPDH* as an internal control. Reactions were carried out in triplicate; error bar represents one standard deviation. **B**. BSS analysis of the *Sox7* promoter in DU 145, LNCaP, and 22Rv1 cells. **C**. Promoter demethylation by 5-aza-2'-deoxycytidine (5AZ) restores *Sox7* expression in LNCaP cells. DU 145 and LNCaP cells were treated with 5AZ, then *Sox7* mRNA expression was measured by qPCR. **D**. Methylation status of the *Sox7* promoter in LNCaP cells, before and after 5-aza-2'-deoxycytidine treatment, as determined by MSP.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript



Figure 4. Sox7 binds to β-catenin and inhibits CRT

A. An illustration of wild-type and mutant Sox7 proteins. Shaded region: HMG (high-mobility group) box; filled box: β-catenin binding motif. Evolutionary conserved sequences within the motif are in bold. **B**. CRT as measured using reporter gene assays with a TCF-responsive reporter (pOT-Flash, 100 ng) or a negative control with a mutated TCF binding site (pOF-Flash, 100 ng). CRT levels were converted to a relative value of 1.0 for cells transfected with β-catenin (100 ng). Different amounts of CMV-Tag2/Sox7 or CMV-Tag2/Sox7-Δ were co-transfected into H1299 with β-catenin. Reactions were carried out in duplicate, and error bars represent one standard deviation. **C**. Sox7 interacts with β-catenin. CMV-Tag2B/Sox7, CMV-Tag2B/Sox7-Δ, CMV-Tag2B/Sox7-M, or CMV-Tag2B plasmids were transfected into HEK293 cells with CMV-β-catenin plasmid, respectively. Cell lysates were harvested 36hrs after transfection, immunoprecipitated by anti-Flag antibody, and the immunoprecipitate probed with anti-Sox7 (top panel) or anti-β-catenin (middle panel) antibodies. Cell lysates were also probed with anti-β-catenin antibody, to determine the amount of input β-catenin (bottom panel). **D**. Sox7 mediates the degradation of active β-catenin. CMV-Tag2B/Sox7 or CMV-Tag2B/Sox7-Δ plasmids were transfected into HEK293 cells with CMV-S33Y-β-catenin plasmid, respectively (left panel). Cell lysates were harvested 48 hrs after transfection and were

probed with monoclonal anti-active-β-catenin antibody (ABC), polyclonal anti-β-catenin antibody (β-cat), anti-Flag antibody (Sox7) and anti-actin antibody. For MG-132 blocking experiment, 20 μM MG132 was added 4 hours before the collection of cell lysate. For transfection with COS-7 cells (right panel), CMV-Tag2B or CMV-Tag2B/Sox7 plasmids were transfected into COS-7 cells with CMV-S33Y-β-catenin plasmid, respectively.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript



Figure 5. Sox7 inactivation in colorectal tumors and cell lines

A. MSP analysis of Sox7 promoter in HCT116 and HT29 colorectal cell lines with MPS PCR primer set#1. **B**. CRT as measured using an experimental procedure similar to the one described for Figure 3b, except that HCT116 cells were not transfected with a β-catenin expression plasmid. **C**. MSP analysis of Sox7 promoter in paired colorectal primary tumors with adjacent normal colon tissues, using MSP PCR primer set#2. * indicates samples with tumor-specific methylation.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript



Figure 6. Transient and stable induction of Sox7 expression in Sox7-null cells inhibits cell proliferation

A. LNCaP, 22Rv1, and HCT116 cells were transfected with either CMV-Tag2/Sox7 plasmid or vector control. Equal numbers of cells were plated in triplicate 24 hrs after transfection, selected with G418, and stained 12 days later with sulforhodamine B. **B**. Estimation of cell numbers by measuring absorbance (y axis) of cells stained with sulforhodamine. Error bars represent one standard deviation of a triplicate assay. **C**. Induction of Sox7 expression in stable C4-2/Tet-Sox7 cell lines. Clones #30 and #33 were grown in the absence (−) or presence (+) of Dox (50 ng/ml). Cell lysates were harvested at 24, 48, and 72 hrs, then analyzed by Western blot. Cell lysates from DU145 and LNCaP cells were used as controls for the Sox7 protein level. Actin was used as loading control. **D**. Equal numbers of cells (4×10^4 cells) from clones #30 and #33 were plated in 6-well plates, grown in culture media in the absence or presence of Dox for 8 days, and stained with sulforhodamine B.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Table 1

Promoter methylation of *Sox7* in prostate cancer cell lines and xenografts.

	Cell line/Xenografts	Promoter Methylation
1	LNCap	**Yes** *
2	22RV1	**Yes** *
3	DU145	No *
4	PC-3	No
5	LAPC-3	**Yes**
6	PC-82	**Yes**
7	CWR21	No
8	CWR22	**Yes** *
9	CWR91	No
10	LuCap23.1	No
11	LuCap23.12	**Yes**
12	LuCap23.8	No
13	LuCap35	No
14	LuCap49	No
15	LuCap58	No
16	LuCap69	**Yes**
17	LuCap70	No
18	LuCap73	Yes
19	LuCap81	**Yes**
20	LuCap86.2	No
21	LuCap92	**Yes**
22	LuCap93	No
23	LuCap96	No
24	LuCap105	**Yes**
25	LuCap115	**Yes**

* Promoter methylation status in these samples was verified by BSS.